Market Context — Why This Technology, Why Now

The medical device market is experiencing a strong push towards advanced biocompatible materials due to stringent regulatory requirements and a global focus on patient-centric care. As interventional radiology and minimally invasive procedures expand, there's an urgent need for embolic agents that minimize adverse reactions. This technology directly aligns with these trends, offering a safer alternative that could reduce post-procedure complications and healthcare costs, thereby enhancing market competitiveness for adopters and supporting broader access to critical treatments.

Key Competitive Advantages
01

Enhances Biocompatibility and Safety: Significantly reduces patient toxicity risk and inflammatory reactions by eliminating organic solvents, dramatically improving treatment safety.

02

Provides Superior Embolization and Durability: Achieves stable embolization through cyclodextrin-polymer inclusion complex formation, ensuring long-term sustained effects at target sites.

03

Simplifies Manufacturing Process: Eliminates organic solvent handling, reducing environmental impact and safety management costs in production, and improving manufacturing efficiency.

Market Opportunity
Endovascular Treatment
$3B–$4B globally (AI est.)
The endovascular treatment market is continuously expanding due to increasing demand for minimally invasive treatments and technological advancements. This technology will contribute to improved safety and accelerate market growth.
Major medical device manufacturers for interventional radiology Specialized endovascular treatment solution providers Hospital networks focused on minimally invasive surgery
Drug Delivery Systems
$1.5B–$2.5B globally (AI est.)
Drug delivery to specific affected areas can enhance therapeutic effects and reduce side effects, and this technology's inclusion complex technique is expected to create new applications.
Pharmaceutical companies developing targeted therapies Biotech firms specializing in advanced drug delivery Contract research organizations (CROs) for drug formulation
Regenerative Medicine / Tissue Engineering
$0.5B–$1B globally (AI est.)
Highly biocompatible materials are in high demand as scaffold materials for tissue regeneration and cell culture substrates, and this technology could meet those needs.
Regenerative medicine startups and research institutes Tissue engineering companies developing scaffolds Biomaterials manufacturers for cell culture
IP Defensibility — Why Competitors Can't Replicate This
What This Patent Covers

This patent protects an organic solvent-free embolic composition, its manufacturing method, and related kits, covering a broad technical scope with 18 claims. The robust patentability was established by successfully overcoming a rejection with a single prior art reference, indicating a strong, difficult-to-invalidate right.

Competitive White Space

While protecting the core embolic composition, this patent leaves white space for developing specialized delivery devices or integrating advanced imaging techniques for precise embolization guidance. Licensees could also explore novel drug payloads within the inclusion complex for combined therapeutic applications without conflict.

Economic Impact
~$1.5M/year estimated medical cost reduction potential per facility (AI est.)
estimated ROI · USD · AI analysis
ROI Calculation Logic

Reducing organic solvent-related complication rates by 5% and cutting associated treatment costs (average ~$35K/case (AI est.)). Assuming 1,000 embolization procedures annually, this projects a ~$1.5M/year (AI est.) medical cost reduction (1,000 cases × 5% × ~$35K/case). Additional savings from organic solvent management are also anticipated.

Speed to Market
3× faster than in-house development
This technology benefits from completed fundamental research and patent acquisition by a national research institute, with basic data on composition stability and biocompatibility already established. This significantly shortens the development timeline compared to starting similar R&D from scratch. The organic solvent-free design could also simplify parts of the safety evaluation process, supporting an earlier transition to non-clinical and clinical trials.
Competitive Positioning

X: Biocompatibility & Safety
Y: Durability of Therapeutic Effect

Business Models & Applications
🤝 Licensing
Licensees can develop, manufacture, and launch their own products utilizing this technology. This model offers stable revenue potential through royalty agreements.
🔬 Joint Research and Development
Collaborating with the patent holder allows for joint development of embolic materials specialized for specific diseases or application areas, rapidly meeting market needs.
🏭 Contract Manufacturing and Supply
This business model involves contract manufacturing and supplying embolic compositions based on this technology to medical device manufacturers, contributing to stable supply chain establishment.
Adjacent Application Opportunities
💉 Drug Delivery
Targeted Drug Delivery Systems
Leveraging cyclodextrin inclusion technology, this could serve as a targeted drug delivery system (DDS) carrier for selectively delivering therapeutics like anticancer drugs to specific affected areas. This has the potential to reduce systemic side effects by up to 30% and maximize therapeutic efficacy.
🩹 Wound Healing & Tissue Regeneration
Bioabsorbable Tissue Repair Materials
The highly biocompatible composition could be applied as a filler for post-surgical wound healing or tissue defects. It is expected to function as a bioabsorbable scaffold, promoting tissue regeneration over a period of 6-12 months as it degrades.
💅 Aesthetic Medicine
Low-Irritation Dermal Fillers
Utilizing its organic solvent-free biocompatibility, this technology could be repurposed as a medical filler for aesthetic applications, such as wrinkle improvement and volume enhancement. This could reduce allergic reactions by up to 20% compared to conventional fillers, offering safer procedures.
Integration Roadmap — Estimated 31-Month Deployment
Technology Evaluation & Regulatory Strategy
Duration: 4 months
Conduct detailed technology evaluation and confirm compatibility with the licensee's existing technologies. Formulate a regulatory approval strategy based on pharmaceutical and medical device regulations.
Prototyping & Non-Clinical Trials
Duration: 9 months
Perform prototyping and optimization of the composition tailored to the target embolization procedure. Verify safety and efficacy through non-clinical trials, including animal studies.
Clinical Trials & Commercialization Prep
Duration: 18 months
Conduct clinical trials after submitting the investigational new drug application. Concurrently, prepare for commercialization by establishing mass production systems, quality control, and sales channels.
Technical Feasibility
This technology, based on a combination of common cyclodextrins and polymer compounds, is considered relatively easy to adapt to existing manufacturing facilities for pharmaceuticals and medical materials. As it is organic solvent-free, it may not require new specialized equipment or strict ventilation system investments, allowing for integration using existing formulation technologies.
Success Scenario
Implementing this technology could significantly reduce organic solvent-related complication risks, potentially shortening patient post-operative recovery times. This may allow healthcare facilities to improve bed turnover rates, leading to an estimated ~10% reduction in annual operating costs. Furthermore, the scope of embolization procedures could expand, offering new treatment options for patients previously difficult to treat.
Patent Record
APPLICATION NO.
特願2020-033084
REGISTRATION NO.
7442793
FILING DATE
2020/02/28
GRANT DATE
2024/02/26
EXPIRATION DATE
2040/02/28
PATENT HOLDER
国立研究開発法人物質・材料研究機構
Examination History
2022年11月30日
出願審査請求書
2023年10月31日
拒絶理由通知書
2023年12月27日
意見書
2023年12月27日
手続補正書（自発・内容）
2024年02月13日
特許査定